Ufuk OKKAY, Irmak FERAH OKKAY

Neuroprotective effect of nicorandil in 6-OHDA induced in vitro model of parkinson's disease

The purpose of this study was to examine the consequences of opening KATP channels using nicorandil in an in vitro 6-OHDA Parkinson’s disease model conducted in SH-SY5Y cells. To establish Parkinson’s disease model in vitro, 200μM 6-OHDA administered to the cells for 24h. Half an hour before the 6-OHDA administration, SH-SY5Y cells were pre-treated with nicorandil (10, 100, 500 and 1000μM). After 1 day, cell viability was determined with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and lactate dehydrogenase (LDH) assays. Oxidative stress was assessed with superoxide dismutase (SOD), glutathione (GSH), reactive oxygen species (ROS) and malondialdehyde (MDA) analyses. We found that 6-OHDA increased LDH leakage, and cellular apoptosis in SH-SY5Y cells. 6-OHDA aggravated oxidative stress by increasing ROS and MDA and eventually promoted apoptosis by increasing mRNA expression levels of Caspase-3 in SH-SY5Y cells, while pretreatment with nicorandil attenuated these toxic effects of 6-OHDA by suppressing oxidative stress and apoptosis. Considering its neuroprotective role in addition to its effects on oxidative stress and apoptosis, nicorandil may be a useful agent in the treatment of Parkinson’s disease.

PDF

___

1. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939-53.
2. Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev. 2017;35:33-50.
3. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
4. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem. 2001;76:1785-93.
5. Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia. 2017;32:533-9.
6. Teshima Y, Akao M, Baumgartner WA, et al. Nicorandil prevents oxidative stress-induced apoptosis in neurons by activating mitochondrial ATPsensitive potassium channels. Brain Res. 2003;990:45-50.
7. Robin E, Simerabet M, Hassoun SM, et al. Postconditioning in focal cerebral ischemia: role of the mitochondrial ATP-dependent potassium channel. Brain Res. 2011;1375:137-46.
8. Zhang F, Cui J, Lv B, et al. Nicorandil protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Int J Mol Med. 2015;36:415-23.
9. Okkay U, Ferah Okkay I, Aydin IC, et al. Effects of Achillea millefolium on cisplatin induced ocular toxicity: an experimental study. Cutan Ocul Toxicol. 2021:1-7.
10. Okkay U, Ferah Okkay I, Cicek B, et al. Achillea millefolium alleviates testicular damage in paclitaxel-intoxicated rats via attenuation of testicular oxido-inflammatory stress and apoptotic responses. Andrologia. 2021;53:e14028.
11. Ravindran S, Swaminathan K, Ramesh A, et al. Nicorandil attenuates neuronal mitochondrial dysfunction and oxidative stress associated with murine model of vascular calcification. Acta Neurobiol Exp (Wars). 2017;77:57-67.
12. Zhao Y, Yang Z, He Y, et al. The KATP channel opener, nicorandil, ameliorates brain damage by modulating synaptogenesis after ischemic stroke. PLoS One. 2021;16:e0246019.
13. Zhao AP, Dong YF, Liu W, et al. Nicorandil inhibits inflammasome activation and Toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells. CNS Neurosci Ther. 2014;20:147-53.
14. 1Tabeshmehr P, Husnain HK, Salmannejad M, et al. Nicorandil potentiates sodium butyrate induced preconditioning of neurons and enhances their survival upon subsequent treatment with H2O2. Transl Neurodegener. 2017;6:29.
15. Maneuf YP, Duty S, Hille CJ, et al. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Exp Neurol. 1996;139:12-6.
16. Xu Z, Yang D, Huang X, et al. Astragaloside IV Protects 6-Hydroxydopamine- Induced SH-SY5Y Cell Model of Parkinson's Disease via Activating the JAK2/STAT3 Pathway. Front Neurosci. 2021;15:631501.
17. Tungalag T, Yang DK. Sinapic Acid Protects SH-SY5Y Human Neuroblastoma Cells against 6-Hydroxydopamine-Induced Neurotoxicity. Biomedicines. 2021;9.
18. Busija DW, Gaspar T, Domoki F, et al. Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. Adv Drug Deliv Rev. 2008;60:1471-7.
19. Casares D, Escribá PV, Rosselló CA. Membrane lipid composition: effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Molecular Sciences. 2019;20:2167.
20. Ahiskali I, Ferah Okkay I, Mammadov R, et al. Effect of taxifolin on cisplatin-associated oxidative optic nerve damage in rats. Cutan Ocul Toxicol. 2021;40:1-6.
21. Kong J, Ren G, Jia N, et al. Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. Eur Neurol. 2013;70:233-41.
22. Ren J, Yuan L, Wang W, et al. Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway. Toxicol Appl Pharmacol. 2019;378:114617.
23. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-94.
24. Owjfard M, Bigdeli MR, Safari A, et al. Effects of nicorandil on neurobehavioral function, BBB integrity, edema and stereological parameters of the brain in the sub-acute phase of stroke in a rat model. J Biosci. 2020;45